UNSPSC 51124306: Quinidine sulfate

This classification denotes a cation channel blocker and antimalarial agent with the molecular formula 2C20H24N2O2.2H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J13S2394HE, chemically known as quinidine sulfate, (2:1) (salt) but more generally known as quinidine sulfate, which bears US NIH Compound Identifier 5768. European Medicines Agency schedules Quinidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15082MIG.

UNSPSC 51124306 Quinidine sulfate is a Commodity code covering branded and generic cardiac and antiarrhythmic pharmaceuticals supplied to state and local emergency medical services, health systems, and public health agencies. State and local governments procure quinidine sulfate and related advanced life support medications through emergency services departments, health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves supplying individual units or bulk quantities of pharmaceutical products with strict expiration-date and shelf-life compliance, warranty periods, and delivery timelines tied to operational need — typically ten calendar days or faster for emergency-response inventory. Issuing bodies include city fire and rescue departments, state health agencies, and multistate cooperative purchasing organizations; recent activity shows both direct municipal procurement (Tampa Fire Rescue) and statewide aggregated purchasing through cooperative vehicles like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP).

Recent activity concentrates in Florida and Minnesota, with multistate participation through cooperative purchasing. The City of Tampa Purchasing Department issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including quinidine-class drugs, epinephrine, adenosine, and diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation includes a 5 percent Small Local Business Enterprise (SLBE) bid discount and required Safety Data Sheets compliant with OSHA Hazard Communication Standards. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with product availability required by May 15, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage state interest in direct contracting models for pharmaceutical supply.